185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)

DEBBRAH, ROSET-BM, TUXEDO-1, and a pooled DB-01, -02, -03 analysis indicate robust efficacy of T-DXd in pts with stable/active BM; however, efficacy in pts with BM is not yet fully established. DB-07 is a phase Ib/II, multicenter, open-label study exploring the safety, tolerability, and antitumor ac...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
Main Authors:	C. Anders, S. Loi, Erika Hamilton, Komal Jhaveri, P. Schmid, Erhan Gökmen, S-A. Im, Cengiz Karaçin, Carlos H. Barrios, Y.H. Park, S. Uzunoğlu, Sarah E. Boston, Adam Konpa, S. Mondal, Fabrice André
פורמט:	Artigo
שפה:	אנגלית
יצא לאור:	2024
גישה מקוונת:	https://doi.org/10.1016/j.esmoop.2024.103207 http://www.esmoopen.com/article/S205970292400975X/pdf
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

היה/י הראשונ/ה לכתוב הערה!

185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)

פריטים דומים